✨ Free AI Report
Sage Therapeutics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Sage Therapeutics, Inc.
Company Research

Sage Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

Sage Therapeutics, Inc. scores 4/10 on the AskCyborg Cyborg Score (Mixed). Sage's 33% increase in prescriptions following recent sales force expansion indicates strong market demand for its products, but profitability remains uncertain as a development-stage commercial entity. Sage reported a 264% increase in Q2 2025 revenue, indicating significant growth in its financial performance. However, the company maintains an operating margin.

What is Sage Therapeutics, Inc.'s industry? Sage Therapeutics, Inc. (sagerx.com) operates in Neurology Drugs. AskCyborg classifies Sage Therapeutics, Inc. under Neurology Drugs in its company registry.

Sage Therapeutics is a biopharmaceutical company focused on brain health medicines and disorders of the brain. The company develops and commercializes innovative treatments for psychiatric and neurological disorders, ...

4/ 10Mixed

Cyborg Score thesis

Sage's 33% increase in prescriptions following recent sales force expansion indicates strong market demand for its products, but...

Read the full analyst-debate transcript →
Industry Neurology Drugs
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Sage Therapeutics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Sage Therapeutics, Inc.

AskCyborg analysts argue the bull and bear cases for Sage Therapeutics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Sage Therapeutics, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Sage Therapeutics, Inc. Overview

Pro stress-test →

Sage Therapeutics is a biopharmaceutical company focused on brain health medicines and disorders of the brain. The company develops and commercializes innovative treatments for psychiatric and neurological disorders, focusing on significant unmet medical needs such as major depressive disorder and postpartum depression.

Strategic Profile

Pro stress-test →

The company has a robust balance sheet enabling continued development of its NMDA and GABAA platform, positioned for long-term growth as total sales are projected to reach approximately $400 million by 2028. The lead commercial product, Zurzuvae, partnered with Biogen, is expected to gain significant traction in the treatment of postpartum depression due to its rapid onset of action and concise treatment regimen.

Competitive Landscape

Pro stress-test →

Sage operates in the psychiatric and neurological disorders treatment space, competing with larger pharmaceutical and biotechnology companies developing CNS medications. Key competitors include Biogen (Zurzuvae partner), Johnson & Johnson, Eli Lilly, and other CNS-focused developers, though Sage differentiates through its NMDA and GABAA receptor platforms.

Industry Context

Sage Therapeutics, Inc. operates in Neurology Drugs.

Key facts

Founded: 2010 · Headquarters: Cambridge, US · Employees: 487 · Revenue: $70.41M · Market cap: $545M

What the analysts stress-tested

The top findings that survived the multi-agent debate for Sage Therapeutics, Inc..

  • (July 2025) Q2 2025 revenue surged 264% with strong prescription growth of 33% following sales force expansion
  • (March 2026) Analyst consensus rating is Hold with price target around $8.40-$9.37
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • July 2025Q2 2025 revenue growth of 264% with net loss reported; beat revenue estimates
  • March 2026Analyst consensus shifted to neutral Hold with 6-7 analysts rating the stock
  • +1 moreTrack every material event for Sage Therapeutics, Inc. as it happens. Explore monitoring →
Get alerted when Sage Therapeutics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

ZurzuvaeCo-marketed postpartum depression treatment; primary commercial focus→TMS Therapy PlatformAlternative neuromodulation for treatment-resistant depression→Ketamine/Esketamine ProgramsRapid-acting depression therapeutics (Spravato)→

Compare Sage Therapeutics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Sage Therapeutics, Inc. operates in Neurology Drugs. See how the rest of the sector scores on the Cyborg framework.

Browse Neurology Drugs research →
NEW · MCP server

Ask your AI assistant about Sage Therapeutics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Sage Therapeutics, Inc. and its top competitor on Cyborg Score”
“What did Sage Therapeutics, Inc. do this quarter?”
“Is Sage Therapeutics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Sage Therapeutics, Inc. do?+
Sage Therapeutics is a biopharmaceutical company focused on brain health medicines and disorders of the brain. The company develops and commercializes innovative treatments for psychiatric and neurological disorders, ...
What is Sage Therapeutics, Inc.'s Cyborg Score?+
Sage Therapeutics, Inc. has a Cyborg Score of 4/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Sage Therapeutics, Inc.'s main competitors?+
Named competitors include Zurzuvae, TMS Therapy Platform, Ketamine/Esketamine Programs. The full competitive landscape is in the AskCyborg report.
How can I get the full Sage Therapeutics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Sage Therapeutics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Sage Therapeutics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.